Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule
Rotavirus infection is a common cause of severe diarrheal disease and a major cause of deaths and hospitalizations among young children. Incidence of rotavirus has declined globally with increasing vaccine coverage. However, it remains a significant cause of morbidity and mortality in low-income...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2022
|
| Subjects: | |
| Online Access: | https://repository.ugm.ac.id/283416/1/250.pdf |
| _version_ | 1826050642144133120 |
|---|---|
| author | Geard, Nicholas Bradhurst, Richard Tellioglu, Nefel Oktaria, Vicka McVernon, Jodie Handley, Amanda Bines, Julie E. |
| author_facet | Geard, Nicholas Bradhurst, Richard Tellioglu, Nefel Oktaria, Vicka McVernon, Jodie Handley, Amanda Bines, Julie E. |
| author_sort | Geard, Nicholas |
| collection | UGM |
| description | Rotavirus infection is a common cause of severe diarrheal disease and a major cause of deaths and
hospitalizations among young children. Incidence of rotavirus has declined globally with increasing
vaccine coverage. However, it remains a significant cause of morbidity and mortality in low-income
countries where vaccine access is limited and efficacy is lower. The oral human neonatal vaccine RV3-
BB can be safely administered earlier than other vaccines, and recent trials in Indonesia have demonstrated
high efficacy. In this study, we use a stochastic individual-based model of rotavirus transmission
and disease to estimate the anticipated population-level impact of RV3-BB following delivery according to
either an infant (2, 4, 6 months) and neonatal (0, 2, 4 months) schedule. Using our model, which
incorporated an age- and household-structured population and estimates of vaccine efficacy derived
from trial data, we found both delivery schedules to be effective at reducing infection and disease. We
estimated 95–96% reductions in infection and disease in children under 12 months of age when vaccine
coverage is 85%. We also estimate high levels of indirect protection from vaccination, including 78%
reductions in infection in adults over 17 years of age. Even for lower vaccine coverage of 55%, we estimate
reductions of 84% in infection and disease in children under 12 months of age. While open questions
remain about the drivers of observed lower efficacy in low-income settings, our model suggests RV3-BB
could be effective at reducing infection and preventing disease in young infants at the population level. |
| first_indexed | 2024-03-14T00:07:48Z |
| format | Article |
| id | oai:generic.eprints.org:283416 |
| institution | Universiti Gadjah Mada |
| language | English |
| last_indexed | 2024-03-14T00:07:48Z |
| publishDate | 2022 |
| publisher | Taylor & Francis |
| record_format | dspace |
| spelling | oai:generic.eprints.org:2834162023-11-21T02:51:30Z https://repository.ugm.ac.id/283416/ Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule Geard, Nicholas Bradhurst, Richard Tellioglu, Nefel Oktaria, Vicka McVernon, Jodie Handley, Amanda Bines, Julie E. Infectious Diseases Rotavirus infection is a common cause of severe diarrheal disease and a major cause of deaths and hospitalizations among young children. Incidence of rotavirus has declined globally with increasing vaccine coverage. However, it remains a significant cause of morbidity and mortality in low-income countries where vaccine access is limited and efficacy is lower. The oral human neonatal vaccine RV3- BB can be safely administered earlier than other vaccines, and recent trials in Indonesia have demonstrated high efficacy. In this study, we use a stochastic individual-based model of rotavirus transmission and disease to estimate the anticipated population-level impact of RV3-BB following delivery according to either an infant (2, 4, 6 months) and neonatal (0, 2, 4 months) schedule. Using our model, which incorporated an age- and household-structured population and estimates of vaccine efficacy derived from trial data, we found both delivery schedules to be effective at reducing infection and disease. We estimated 95–96% reductions in infection and disease in children under 12 months of age when vaccine coverage is 85%. We also estimate high levels of indirect protection from vaccination, including 78% reductions in infection in adults over 17 years of age. Even for lower vaccine coverage of 55%, we estimate reductions of 84% in infection and disease in children under 12 months of age. While open questions remain about the drivers of observed lower efficacy in low-income settings, our model suggests RV3-BB could be effective at reducing infection and preventing disease in young infants at the population level. Taylor & Francis 2022-11-30 Article PeerReviewed application/pdf en https://repository.ugm.ac.id/283416/1/250.pdf Geard, Nicholas and Bradhurst, Richard and Tellioglu, Nefel and Oktaria, Vicka and McVernon, Jodie and Handley, Amanda and Bines, Julie E. (2022) Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule. Human Vaccines and Immunotherapeutics, 18 (6). p. 2139097. 10.1080/21645515.2022.2139097 |
| spellingShingle | Infectious Diseases Geard, Nicholas Bradhurst, Richard Tellioglu, Nefel Oktaria, Vicka McVernon, Jodie Handley, Amanda Bines, Julie E. Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule |
| title | Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule |
| title_full | Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule |
| title_fullStr | Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule |
| title_full_unstemmed | Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule |
| title_short | Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule |
| title_sort | model based estimation of the impact on rotavirus disease of rv3 bb vaccine administered in a neonatal or infant schedule |
| topic | Infectious Diseases |
| url | https://repository.ugm.ac.id/283416/1/250.pdf |
| work_keys_str_mv | AT geardnicholas modelbasedestimationoftheimpactonrotavirusdiseaseofrv3bbvaccineadministeredinaneonatalorinfantschedule AT bradhurstrichard modelbasedestimationoftheimpactonrotavirusdiseaseofrv3bbvaccineadministeredinaneonatalorinfantschedule AT tellioglunefel modelbasedestimationoftheimpactonrotavirusdiseaseofrv3bbvaccineadministeredinaneonatalorinfantschedule AT oktariavicka modelbasedestimationoftheimpactonrotavirusdiseaseofrv3bbvaccineadministeredinaneonatalorinfantschedule AT mcvernonjodie modelbasedestimationoftheimpactonrotavirusdiseaseofrv3bbvaccineadministeredinaneonatalorinfantschedule AT handleyamanda modelbasedestimationoftheimpactonrotavirusdiseaseofrv3bbvaccineadministeredinaneonatalorinfantschedule AT binesjuliee modelbasedestimationoftheimpactonrotavirusdiseaseofrv3bbvaccineadministeredinaneonatalorinfantschedule |